ACTL7B

Across TCGA pan-cancer cohorts, ACTL7B RNA differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of ACTL7B’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where ACTL7B RNA is more highly expressed in tumor relative to normal tissue. In most cancer types ACTL7B is over-expressed in tumor, although a few such as LUAD and THCA show the opposite, repressed pattern.

HNSC, COAD, and LUAD are the cancer types where ACTL7B tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ACTL7B RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Female	II,III,IV	+0.028	.019	6	view →
COAD	All	II,III,IV	+0.020	.020	5	view →
LUAD	Male	II,III,IV	−0.034	.016	3	view →
THCA	Male	All	−0.030	<.001	3	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

ACTL7B–HNSC

Open the HNSC breakdown →